Targeting mTOR for cancer therapy
H Hua, Q Kong, H Zhang, J Wang, T Luo… - Journal of hematology & …, 2019 - Springer
Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival,
metabolism, and immunity. mTOR is usually assembled into several complexes such as …
metabolism, and immunity. mTOR is usually assembled into several complexes such as …
Inhibition of mTOR signaling and clinical activity of rapamycin in head and neck cancer in a window of opportunity trial
TA Day, K Shirai, PE O'Brien, MG Matheus… - Clinical Cancer …, 2019 - AACR
Purpose: We studied the impact of mTOR signaling inhibition with rapamycin in head and
neck squamous cell carcinoma (HNSCC) in the neoadjuvant setting. The goals were to …
neck squamous cell carcinoma (HNSCC) in the neoadjuvant setting. The goals were to …
Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway
Z Yang, J Liao, BA Carter-Cooper, RG Lapidus… - BMC cancer, 2019 - Springer
Background We investigated the role of the ETS-1 transcription factor in Head and Neck
Squamous Cell Carcinoma (HNSCC) in multiple cisplatin-resistant HNSCC cell lines …
Squamous Cell Carcinoma (HNSCC) in multiple cisplatin-resistant HNSCC cell lines …
PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
V Sambandam, MJ Frederick, L Shen, P Tong… - Clinical Cancer …, 2019 - AACR
Purpose: Head and neck squamous cell carcinoma (HNSCC) is driven largely by the loss of
tumor suppressor genes, including NOTCH1, but lacks a biomarker-driven targeted therapy …
tumor suppressor genes, including NOTCH1, but lacks a biomarker-driven targeted therapy …
PLGA nanoparticle-based docetaxel/LY294002 drug delivery system enhances antitumor activities against gastric cancer
J Cai, K Qian, X Zuo, W Yue, Y Bian… - Journal of …, 2019 - journals.sagepub.com
Docetaxel (TXT) is acknowledged as one of the most important chemotherapy agents for
gastric cancer (GC). PI3K/AKT signaling is frequently activated in GC, and its inhibitor …
gastric cancer (GC). PI3K/AKT signaling is frequently activated in GC, and its inhibitor …
[HTML][HTML] Inhibition of cisplatin-resistant head and neck squamous cell carcinoma by combination of Afatinib with PD0325901, a MEK inhibitor
X Lin, J Liao, Z Yang, X Fan, KJ Cullen… - American Journal of …, 2019 - ncbi.nlm.nih.gov
ErbB family members that contain EGFR, HER2, HER3 and HER4 play important roles in
many cancer types, including head and neck; however, inhibition of these receptors by small …
many cancer types, including head and neck; however, inhibition of these receptors by small …
Retraction: A005, a novel inhibitor of phosphatidylinositol 3-kinase/mammalian target of rapamycin, prevents osteosarcoma-induced osteolysis.
Z Lian, J Han, L Huang, C Wei, Y Fan, J Xu… - …, 2019 - search.ebscohost.com
Osteosarcoma is the most frequent primary bone tumor in children and adolescents. The
phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling …
phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling …
Examining Mechanisms of Sensitivity and Resistance to Phosphatidylinositol 3-kinase inhibitors in Head and Neck Squamous Cell Carcinoma
N Michmerhuizen - 2019 - deepblue.lib.umich.edu
Head and neck squamous cell carcinoma (HNSCC) is a common and debilitating form of
cancer with few effective treatment options. HNSCC tumors display a complex array of …
cancer with few effective treatment options. HNSCC tumors display a complex array of …
Der PI3K-Signalweg als therapeutische Zielstruktur von Leiomyosarkomen-Präklinische Validierung mithilfe humaner Xenograftmodelle
S Knospe - 2019 - refubium.fu-berlin.de
Leiomyosarkome (LMS) sind eine der am häufigsten auftretenden, mesenchymalen
Tumoren des Menschen. Sie weisen eine glattmuskuläre Differenzierung auf und können …
Tumoren des Menschen. Sie weisen eine glattmuskuläre Differenzierung auf und können …